Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer

By afschroeder • November 8, 2025

Lloyd MR, Weipert CM, Ali A, Solomon SR, Saha J, Lipsyc-Sharf MD, Hamilton EP, Kalinsky K, Brufsky AM, Bardia A, Zhang N, Wander SA. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res. 2025 Nov 7. doi: 10.1158/1078-0432.CCR-25-3033. Epub ahead of print. PMID: 41201834.

Tags: Hematology/Oncology, Publications

Related Posts

A Pilot Test of an AI Voice-Driven Simulation With Feedback for Medical Students to Practice Discussing Diagnostic Mammogram Results With Patients

Comulada WS, Ganz PA, Huang YM, Weisman D, Sugarman A, Lee D, Shah S, Gelberg L. A Pilot Test of an AI Voice-Driven Simulation With[...]

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose[...]

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster[...]